EnGeneIC and Singapore Institute of Advanced Medicine Holdings Forge Strategic Partnership to Revolutionise Cancer Treatment in Asia
SYDNEY, Australia, June 06, 2024 (GLOBE NEWSWIRE) -- EnGeneIC, a clinical-stage biopharmaceutical company pioneering the development of a First-in-Class targeted nanocell for cancer therapy has today announced strategic partnerships with Singapore Institute of Advanced Medicine Holdings (SAM) and Singapore Medical Incorporation (SMI).
- SYDNEY, Australia, June 06, 2024 (GLOBE NEWSWIRE) -- EnGeneIC, a clinical-stage biopharmaceutical company pioneering the development of a First-in-Class targeted nanocell for cancer therapy has today announced strategic partnerships with Singapore Institute of Advanced Medicine Holdings (SAM) and Singapore Medical Incorporation (SMI).
- The partnerships will bring significant new funding to allow EnGeneIC to immediately progress its clinical trial programmes in Australia and the USA.
- Further, the agreements aim to accelerate the clinical development, manufacture and commercialisation of EnGeneIC’s proprietary technology, EnGeneIC Dream Vector (EDVTM) for cancer treatment across Asia.
- By combining our not inconsiderable strengths, we aim to deliver revolutionary cancer treatments that offer new hope to patients throughout the region.